- Home
- MTZ vs INCY Comparison
MTZ vs INCY Comparison
Compare MTZ & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTZ | INCY |
|---|---|---|
| Founded | 1929 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 17.0B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | MTZ | INCY |
|---|---|---|
| Price | $219.26 | $102.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | ★ $228.89 | $90.71 |
| AVG Volume (30 Days) | 753.0K | ★ 2.0M |
| Earning Date | 10-30-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 270.77 | ★ 3878.02 |
| EPS | 4.20 | ★ 5.90 |
| Revenue | ★ $13,762,473,000.00 | $4,813,105,000.00 |
| Revenue This Year | $15.48 | $19.59 |
| Revenue Next Year | $10.21 | $10.88 |
| P/E Ratio | $52.30 | ★ $17.37 |
| Revenue Growth | 12.99 | ★ 18.09 |
| 52 Week Low | $99.70 | $53.56 |
| 52 Week High | $224.03 | $109.28 |
Technical Indicators
Market Signals| Indicator | MTZ | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 54.83 |
| Support Level | $207.94 | $100.55 |
| Resistance Level | $214.00 | $107.61 |
| Average True Range (ATR) | 8.12 | 2.94 |
| MACD | 2.47 | -0.98 |
| Stochastic Oscillator | 90.92 | 45.19 |
Price Performance
Historical ComparisonAbout MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.